


PHARMACEUTICAL 2022

Monopar Therapeutics Rank 125 of 466





Monopar Therapeutics



PHARMACEUTICAL 2022



Monopar Therapeutics Rank 125 of 466

The relative strengths and weaknesses of Monopar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Monopar Therapeutics compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 81% points. The greatest weakness of Monopar Therapeutics is the variable Net Income, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 212%, being 135% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	20,522
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	0
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	4.7
Other Expenses	0
Other Liabilities	1,581
Other Net Income	24
Other Revenues	0
Property and Equipment	0
Research and Development	6,493
Selling, General and Administrative Expense	2,634

Output Variable	Value in 1000 USD
Assets	20,522
Liabilities	1,581
Expenses	9,127
Revenues	0
Stockholders Equity	18,941
Net Income	-9,103
Comprehensive Net Income	-9,101
Economic Capital Ratio	212%

